Medicine recalls
|
| |
| The United States: Biota Biosciences issues voluntary nationwide recall of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables because they were marketed without FDA approval |
| |
The US Food and Drug Administration (FDA) announces that Biota Biosciences is voluntarily recalling the following lots of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables to the customer level. These injectable products are being recalled because they were marketed without FDA approval. The products claims on our website make these products unapproved new drugs. Further, the products are misbranded because the labeling fails to bear adequate directions for use. The affected products are:
- Cannabidiol (CBD) Complex 40mg (lot number: 2H071219P)
- Cannabidiol (CBD) Complex 500mg (lot number: 10102019P)
- Curcumin Complex 40mg (lot number: 2H071219CCD)
- Curcumin Complex 500mg (lot number: 0712019CCD)
- Cannabidiol + Curcumin 500mg (lot number: 10102019PC)
Unapproved new drugs injected into the bloodstream for which safety and efficacy have not been established could pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Biota Biosciences has not received any reports of adverse events related to this recall.
Cannabidiol (CBD) Complex was marketed to suppress pain and aid in the detoxification processes as a promising therapeutic for a wide array of disorders such as epilepsy, including many challenging neuropathy conditions. Curcumin Complex was marketed as a potent anti-inflammatory and antioxidant that may also help improve symptoms of depression and arthritis. Cannabidiol + Curcumin was marketed as a more efficient therapeutic effect. The product was sold to certified practitioners who further administer to customers. The product is packaged in 10 ml sterile vials.
Please refer to the following website in FDA for details:
http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/biota-biosciences-issues-voluntary-nationwide-recall-cannabidiol-cbd-complex-curcumin-complex-and
In Hong Kong, the above products are not registered pharmaceutical products.
Ends/Thursday, May 21, 2020
Issued at HKT 15:00
|
| |
